Eli Lilly, Boehringer Ingelheim revise prolific diabetes pact, firing all cylinders for blockbuster Jardiance franchise
Eli Lilly bet big to enlist Boehringer Ingelheim as an ally in establishing a diabetes kingdom back in 2011, paying €300m ($390m) to get its …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
